LACUTAMAB IN PATIENTS (PTS) WITH ADVANCED MYCOSIS FUNGOIDES (MF) ACCORDING TO KIR3DL2 EXPRESSION: EARLY RESULTS FROM THE TELLOMAK PHASE 2 TRIAL. (17th June 2021) - Bagot, M.; Kim, Y.; Zinzani, P. L.; Dalle, S.; Beylot‐barry, M.; Ortiz‐Romero, P. L; Cambalia, A.; Dereure, O.; Mortier, L.; Jacobsen, E.; Rotolo, F.; Azim, H. A; et al.